Massivemarkets

VKTX

Viking Therapeutics, Inc

Nasdaq · usd

$24.40-1.43 (-5.54%)
At close · 15-minute delayed
$24.45+0.05 (+0.20%)
As of 7:59:58 PM EDT on Oct 23, 2026 · After hours

Viking Therapeutics, Inc (VKTX) trades at $24.40 (-5.54%) as of 7:59:58 PM EDT on Oct 23, 2026, -33.61% over the past month. Market cap is $3.28B, with 2.2 days to cover in short interest.

Stock performance

How Viking Therapeutics, Inc (VKTX) stock has performed from one day to one year, with its 52-week range.

-5.24%
-$1.35 over 1D
$24.48$24.92$25.36$25.804:00 AM10:25 AM1:00 PM3:30 PM8:00 PM$24.45
1D
-5.54%
1W
-3.06%
1M
-33.61%
YTD
-30.64%
1Y
-32.09%
52-wk range
$24.36 – $43.15

Key statistics

Today's trading snapshot for VKTX: day range, open, previous close, volume and market cap.

Day range
$24.36 – $25.74
Open
$25.54
Prev close
$25.83
Volume
4.68M
Market cap
$3.28B
Shares out
125.99M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Viking Therapeutics, Inc: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
8.04
P/FCF
—
ROE
-131.0%
ROA
-102.5%
Debt/Equity
0.00
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events Viking Therapeutics, Inc has disclosed to the SEC on Form 8-K.

  • Investor communicationsSep 28, 2026

    The Company currently intends to use the net proceeds from the Equity Offering and the Debt Offering for the continued clinical development, advancement and commercialization of its VK2735 program, the continued clinical development and advancement of its VK3019 program and for other general research and development, working capital and general corporate purposes.

  • Business developmentsSep 22, 2026

    On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735.

  • Shareholder meetingsMay 26, 2026

    On May 19, 2026, Viking Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. At the Annual Meeting, the Company's stockholders considered three proposals... As a result, the Company's stockholders voted to elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the Company's 2029 annual meeting of stockholders.

  • Business developmentsAug 19, 2025

    On August 19, 2025, Viking Therapeutics, Inc. issued a press release announcing top-line results from the Company's Phase 2 clinical trial of the oral tablet formulation of VK2735.

  • Shareholder meetingsMay 27, 2025

    On May 20, 2025, Viking Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. At the Annual Meeting, the Company's stockholders considered three proposals... As a result, the Company's stockholders voted to elect Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors to serve until the Company's 2028 annual meeting of stockholders.

VKTX short interest

How heavily VKTX is shorted: shares short, days to cover and average daily volume.

Days to cover
2.2
Short interest
25.92M
Avg volume
12.01M

As of · reported to FINRA twice monthly.

VKTX news

The latest news and headlines about Viking Therapeutics, Inc (VKTX).

Frequently asked questions

What is the Viking Therapeutics, Inc (VKTX) stock price today?

Viking Therapeutics, Inc (VKTX) is trading at $24.40 (-5.54% on the day) as of 7:59:58 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Viking Therapeutics, Inc?

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products.

What is the short interest in VKTX?

As of Sep 30, 2026, VKTX has 25.92M shares short and 2.2 days to cover.

What exchange is VKTX listed on?

Viking Therapeutics, Inc (VKTX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of VKTX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a VKTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.